Tempus AI Inc. has announced a new research collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a nonprofit foundation focused on advancing treatment options for follicular lymphoma. This partnership marks Tempus' first study with a nonprofit foundation and aims to create a comprehensive dataset by integrating real-world clinical data with advanced molecular profiling. The goal is to uncover biological drivers of follicular lymphoma and support the development of more personalized therapies to improve patient outcomes globally.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251114839914) on November 14, 2025, and is solely responsible for the information contained therein.